Full-Time

Junior Territory Sales Manager

Healthcare

Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

No salary listed

Letchworth Garden City, UK + 3 more

More locations: Essex, UK | Harlow, UK | Welwyn Garden City, UK

Remote

Must reside within the Hertfordshire and Essex (South) territory.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Data Analysis

Get referred to Dexcom

See people who can refer or advise you

Requirements
  • You must have the Right to Work in the United Kingdom. Sponsorship is not available for this role.
  • Applicants must reside within the Hertfordshire and Essex (South) territory; candidates living outside this territory will not be considered.
  • Typically requires a Bachelor’s degree and a minimum of 2-5 years of related experience.
  • Hold a full UK driving licence with no more than 3 points.
Responsibilities
  • drive recommendations and adoption of Dexcom CGM products across Community and Primary Care settings.
  • support implementation of local ICS/CCG real-time CGM policies by driving new patient initiations and appropriate switches from competitor technologies.
  • build effective relationships with healthcare professionals, key decision makers, and internal Dexcom stakeholders to deliver territory objectives.
  • provide product training and in-servicing to relevant healthcare professionals using innovative and compliant engagement methods.
  • manage your territory strategically, prioritising accounts and activities based on customer and business needs.
  • use CRM and available data insights daily to identify opportunities, track activity, and support sustainable sales growth.
  • contribute to increasing Dexcom market share and achieving sensor sales targets in line with company expectations and values.
Desired Qualifications
  • Exposure to diabetes, medical devices, or the NHS environment.
  • Experience supporting Primary or Community Care accounts.
  • A degree in Life Sciences, Business, or a related field, or evidence of relevant professional development.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dexcom secured coverage for seven million non-insulin patients across major U.S. PBMs.
  • Q2 2026 revenue reached $1.31 billion; management raised full-year guidance to $5.25 billion.
  • Health Canada cleared G7 15 Day, and international Stelo expansion starts in 2026.

What critics are saying

  • Dexcom faces 2025 FDA warning, Class I recalls, and 2026 class-action litigation.
  • Abbott’s Libre remains the main rival, pressuring Dexcom’s pricing, share, and physician loyalty.
  • G8 depends on 2027 FDA filing; any sensor failure or delay damages credibility.

What makes Dexcom unique

  • Dexcom’s G7 15-day sensor extends wear to 15.5 days and lowers sensor swaps.
  • Stelo gives Dexcom direct-to-consumer non-insulin entry, expanding beyond prescription diabetes management.
  • Dexcom’s ecosystem now bundles CGM, CLARITY analytics, and Nutrisense nutrition coaching.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Jul 31st, 2026
DexCom secures coverage for 7M patients, raises growth guidance after Q2 2026 results

DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.

Yahoo Finance
Jul 31st, 2026
DexCom's Q2 revenue climbs 13% to $1.31B, raises full-year guidance to $5.25B

DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.

Yahoo Finance
Jul 30th, 2026
Dexcom raises annual revenue forecast to $5.25B on strong glucose monitor demand

Dexcom raised its full-year revenue forecast on Thursday, driven by strong demand for its continuous glucose monitors. The medical device maker now expects annual revenue between $5.18 billion and $5.25 billion, up from its previous range of $5.16 billion to $5.25 billion. The company reported second-quarter revenue of $1.31 billion, a 13% increase year-over-year, beating analyst estimates of $1.29 billion. Adjusted profit reached 70 cents per share, surpassing the 61-cent estimate. Rising awareness of diabetes care, improved insurance coverage, and consumer preference for finger-prick-free technology have boosted demand for continuous glucose monitors. Dexcom competes in this market alongside Medtronic and Abbott Laboratories. Following the announcement, Dexcom's shares rose over 4% in extended trading.

Ticker Report
Jul 20th, 2026
SEB Asset Management AB Makes New $23.68 Million Investment in DexCom, Inc. $DXCM

SEB Asset Management AB purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 377,064 shares of the medical device company’s stock, valued at approximately $23,680,000. A number of other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a […]

Yahoo Finance
Jul 13th, 2026
Dexcom G7 15 Day wins Health Canada approval as longest-lasting CGM with 15.5 days of wear

Dexcom has received Health Canada authorisation for its G7 15 Day Continuous Glucose Monitoring System for adults 18 and older with diabetes. The device provides real-time glucose readings for 15.5 days, making it the longest-lasting CGM system authorised by Health Canada. The system features an overall mean absolute relative difference of 8.0% and requires fewer sensor changes per month than previous models. It includes waterproof design, direct connectivity to Apple Watch, and a 12-hour grace period for sensor replacement. The product is not yet available for purchase. Dexcom Canada said it is focusing on ensuring healthcare providers and patients have proper support and education before launch. More than four million Canadians live with diabetes.